ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

PRPH ProPhase Labs Inc

0.6105
-0.0426 (-6.52%)
21 Dec 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
ProPhase Labs Inc NASDAQ:PRPH NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.0426 -6.52% 0.6105 0.60 0.79 0.699 0.625 0.65 319,202 05:00:02

ProPhase Labs Inc. to Present Third Quarter 2024 Financial Results on November 13, 2024

11/11/2024 2:52pm

GlobeNewswire Inc.


ProPhase Labs (NASDAQ:PRPH)
Historical Stock Chart


From Oct 2024 to Dec 2024

Click Here for more ProPhase Labs Charts.

ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”), a next generation biotech, genomics and diagnostics company, today announced that they will be presenting third quarter 2024 financial results on a virtual conference call hosted by Renmark Financial on November 13, 2024 at 11:00 AM EST. A press release detailing these results will be issued prior to the virtual conference call. ProPhase Labs Inc. welcomes stakeholders, investors, and other individual followers to register and attend this live event.

Investors interested in participating in this live event will need to register using the link below. After the event, a replay will be available on the company’s investor website.

REGISTER HERE: https://www.renmarkfinancial.com/events/third-quarter-2024-results-virtual-conference-call-nasdaq-prph-B7BiIzlRxh

  • To ensure smooth connectivity, please access this link using the latest version of Google Chrome.

About ProPhase LabsProPhase Labs Inc. (Nasdaq: PRPH) (“ProPhase”) is a next-generation biotech, genomics and diagnostics company. Our goal is to create a healthier world with bold action and the power of insight. We believe we’re revolutionizing healthcare with industry-leading Whole Genome Sequencing solutions, while developing potential game changer diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. Our world-class CLIA labs and cutting-edge diagnostic technology provide wellness solutions for healthcare providers and consumers. We develop, manufacture, and commercialize health and wellness solutions to enable people to live their best lives. We are committed to executional excellence, smart diversification, and a synergistic, omni-channel approach. ProPhase Labs’ subsidiaries and their strategic synergies highlight our potential for long-term value.

Media Relations and Institutional Investor Contact:

ProPhase Labs, Inc.267-880-1111investorrelations@prophaselabs.com

Retail Investor Relations Contact:

Renmark Financial CommunicationsJohn Boidman212-812-7680Jboidman@renmarkfinancial.com

Source: ProPhase Labs, Inc.

1 Year ProPhase Labs Chart

1 Year ProPhase Labs Chart

1 Month ProPhase Labs Chart

1 Month ProPhase Labs Chart

Your Recent History

Delayed Upgrade Clock